Series B · Biotech · Copenhagen, Denmark · Founded 2017 · 55–65 employees
Adcendo is a clinical-stage biotech company developing first and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need. The company was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet, focusing on targeting the uPARAP receptor which was originally identified and cloned by its scientific founders. Their lead candidate ADCE-D01 has received FDA Fast Track designation for treating soft tissue sarcoma, and they recently completed a $135 million Series B funding round in November 2024. The company has raised over $240 million in total funding since 2021 and is advancing multiple differentiated ADC candidates through clinical trials.
No open roles listed right now.